Highlight
– The 2026 AHA/ACC dyslipidemia guideline incorporates the PREVENT calculator for 10-year ASCVD risk evaluation, superseding the Pooled Cohort Equations.
– Coronary artery calcium (CAC) scoring effectively stratifies atherosclerotic cardiovascular disease (ASCVD) risk, especially in patients with borderline statin eligibility.
– Individuals with absent CAC still experience significant ASCVD event rates when statin therapy is guideline-recommended, suggesting CAC 0 should not replace guideline-based statin initiation.
– CAC scoring provides nuanced risk refinement near statin treatment thresholds, guiding prevention intensity and personalized therapy decisions.
